1 P. Priestley et al, Pan-cancer whole genome analyses of metastatic solid tumours, Nature, 2019 Nov;575(7781):210-216.
2 A-M. Tsimberidou et al., Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark
analyses, Clin Cancer Res. 2014 Sep 15;20(18):4827-36
3 C. Massard et al., High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov.
2017 Jun;7(6):586-595
4 J. Rodon et al., Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial, Nat Med. 2019 May;25(5):751-758.
5 K. Christofyllakis et al., Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive
tumour genomic profiling and the role of clinical utility frameworks (Review), Mol Clin Oncol. 2022 Jan;16(1):21
6 L. Jennings et al., Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels: A Joint Consensus Recommendation of the Association
for Molecular Pathology and College of American Pathologists, J Mol Diagn, 2017 May; 19(3):341-365.
7 G. Mendiratta et al., Cancer gene mutation frequencies for the U.S. population, Nat Commun. 2021; 12: 5961.
8 L. Nguyen et al., Pan-cancer landscape of homologous recombination deficiency, Nat Commun. 2020 Nov 4;11(1):5584.
9 A. Zehir et al., Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med. 2017 Jun;23(6):703-713.
10 S. Trabucco et al., A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000
Microsatellite Instability–High Cases in 67,000 Patient Samples, J Mol Diagn. 2019 Nov; 21(6): 1053–1066.